Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 2
2007 4
2008 2
2009 7
2010 11
2011 17
2012 10
2013 15
2014 18
2015 20
2016 23
2017 26
2018 24
2019 16
2020 28
2021 22
2022 6
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Results by year

Filters applied: . Clear all
Page 1
Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure.
Murakami S, Imamura M, Uchida T, Suehiro Y, Namba M, Fujii Y, Uchikawa S, Teraoka Y, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Kawaoka T, Miki D, Hayes NC, Tsuge M, Aikata H, Ohira M, Ohdan H, Oka S. Murakami S, et al. Among authors: tsuge m. Hepatol Int. 2023 Oct;17(5):1225-1232. doi: 10.1007/s12072-023-10532-x. Epub 2023 Apr 26. Hepatol Int. 2023. PMID: 37101102
Reply from the authors.
Kawaoka T, Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y, Fuji Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chayama K, Aikata H. Kawaoka T, et al. Among authors: tsuge m. Hepatol Res. 2020 Dec;50(12):1393. doi: 10.1111/hepr.13578. Hepatol Res. 2020. PMID: 33280200 No abstract available.
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Yano S, Kawaoka T, Yamasaki S, Johira Y, Kosaka M, Shirane Y, Miura R, Amioka K, Naruto K, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Miki D, Tsuge M, Teraoka Y, Kouno H, Takaki S, Mori N, Tsuji K, Oka S. Yano S, et al. Among authors: tsuge m. Cancers (Basel). 2023 Nov 14;15(22):5406. doi: 10.3390/cancers15225406. Cancers (Basel). 2023. PMID: 38001666 Free PMC article.
Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment.
Tamura Y, Ono A, Nakahara H, Hayes CN, Fujii Y, Zhang P, Yamauchi M, Uchikawa S, Teraoka Y, Uchida T, Fujino H, Nakahara T, Murakami E, Tsuge M, Serikawa M, Miki D, Kawaoka T, Okamoto W, Imamura M, Nakamura Y, Awai K, Kobayashi T, Ohdan H, Fujita M, Nakagawa H, Chayama K, Aikata H, Oka S. Tamura Y, et al. Among authors: tsuge m. Cancers (Basel). 2023 Aug 24;15(17):4234. doi: 10.3390/cancers15174234. Cancers (Basel). 2023. PMID: 37686510 Free PMC article.
Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma.
Yamauchi M, Ono A, Amioka K, Fujii Y, Nakahara H, Teraoka Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Okamoto W, Miki D, Kawaoka T, Tsuge M, Imamura M, Hayes CN, Ohishi W, Kishi T, Kimura M, Suzuki N, Arihiro K, Aikata H, Chayama K, Oka S. Yamauchi M, et al. Among authors: tsuge m. Commun Med (Lond). 2023 Oct 25;3(1):152. doi: 10.1038/s43856-023-00390-x. Commun Med (Lond). 2023. PMID: 37880538 Free PMC article.
Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes.
Ogawa Y, Nakahara T, Ando Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, Murakami E, Kawaoka T, Miki D, Yamauchi M, Tsuge M, Imamura M, Oka S. Ogawa Y, et al. Among authors: tsuge m. Eur J Gastroenterol Hepatol. 2023 Sep 1;35(9):989-996. doi: 10.1097/MEG.0000000000002588. Epub 2023 Jun 6. Eur J Gastroenterol Hepatol. 2023. PMID: 37395206
The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
Chihiro K, Kawaoka T, Uchikawa S, Kinami T, Yamasaki S, Kosaka M, Johira Y, Yano S, Amioka K, Naruto K, Ando Y, Yamaoka K, Teraoka Y, Uchida T, Fujino H, Nakahara T, Ono A, Murakami E, Okamoto W, Yamauchi M, Miki D, Tsuge M, Imamura M, Aikata H, Oka S. Chihiro K, et al. Among authors: tsuge m. Oncology. 2023;101(8):491-501. doi: 10.1159/000530991. Epub 2023 Jul 10. Oncology. 2023. PMID: 37429266
227 results